Tango Therapeutics (TNGX) financial statements
Tango Therapeutics reported revenue of $62M in fiscal 2025, up 52.1% a year over 5 years.
Net income was -$102M and the operating margin -178.4%, against -681.8% in 2020.
Free cash flow was -$140M.
The diluted share count rose 264% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Tango Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8M | $37M | $25M | $37M | $42M | $62M |
| Research and development | $50M | $78M | $106M | $115M | $144M | $132M |
| Selling, general and admin | $10M | $18M | $30M | $36M | $44M | $42M |
| Operating income | -$52M | -$58M | -$111M | -$114M | -$146M | -$111M |
| Pre-tax income | -$52M | -$58M | -$108M | -$102M | -$130M | -$102M |
| Income tax | $0 | $292,000 | $54,000 | $134,000 | $208,000 | $4,000 |
| Net income | -$52M | -$58M | -$108M | -$102M | -$130M | -$102M |
| EPS (diluted) | -$1.63 | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Diluted shares | 32M | 62M | 88M | 95M | 109M | 116M |
| Operating margin | -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Net margin | -678.8% | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
Balance sheet
Fiscal years, from Tango Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $190M | $485M | $366M | $337M | $258M | $343M |
| Receivables | $2M | $2M | $2M | — | — | — |
| Total current assets | $194M | $492M | $375M | $347M | $266M | $354M |
| Property, plant and equipment | $4M | $5M | $11M | $10M | $8M | $7M |
| Total assets | $207M | $500M | $436M | $403M | $316M | $399M |
| Total current liabilities | $41M | $41M | $56M | $46M | $38M | $22M |
| Total liabilities | $169M | $155M | $187M | $149M | $117M | $53M |
| Shareholders' equity | $39M | $345M | $249M | $253M | $200M | $346M |
| Net debt | -$28M | -$143M | -$60M | -$66M | -$70M | -$112M |
Cash flow
Fiscal years, from Tango Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $70M | -$60M | -$109M | -$118M | -$132M | -$139M |
| Capital spending | $1M | $2M | $8M | $2M | $754,000 | $1M |
| Free cash flow | $69M | -$61M | -$117M | -$120M | -$132M | -$140M |
| Stock-based compensation | $2M | $8M | $14M | $19M | $29M | $26M |
| Free cash flow margin | 900.8% | -165.7% | -469.7% | -327.2% | -314.4% | -224.3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TNGX.
Open TNGX in InvestinglyQuestions
What was Tango Therapeutics's revenue in 2025?
$62M in fiscal 2025, from its 10-K filing.
How much free cash flow does Tango Therapeutics generate?
-$140M in fiscal 2025 (operating cash flow minus capital spending).
From Tango Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.